Trial Profile

Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eltrombopag (Primary)
Indications Thrombocytopenia
Focus Therapeutic Use

Most Recent Events

01 Nov 2021 Results (n=12) from NCT01757145 and NCT01940562 whehter Eltrombopag enhances platelet engraftment in adult and pediatric patients undergoing allogeneic cord blood transplantation, published in the Leukemia and Lymphoma
19 Jan 2019 New trial record
04 Dec 2018 Results (n=12) from NCT01757145, NCT01940562 , in both adults and children hypothesizing that eltrombopag would enhance platelet engraftment after UCB transplantation presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com